Myriad Genetic Laboratories Inc. said the Japanese Ministry of Health, Labour, and Welfare has granted a second manufacturing and marketing approval for Myriad’s BRACAnalysis Diagnostic System as a companion diagnostic with the PARP inhibitor, Lynparza (olaparib).
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe